Johnson & Johnson (NYSE:JNJ) Shares Down 1.1% – Here’s What Happened

Posted by Francis Steltz on Oct 2nd, 2026

Johnson & Johnson (NYSE:JNJ – Get Free Report) shares fell 1.1% during mid-day trading on Friday. The company traded as low as $255.12 and last traded at $255.9410. 10,176,026 shares changed hands during mid-day trading, an increase of 27% from the average session volume of 7,992,505 shares. The stock had previously closed at $258.66.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: ICOTYDE delivers durable psoriasis results: New Phase 3 ICONIC-TOTAL data showed sustained skin clearance through two years. At Week 112, 70% of patients achieved clear or almost clear skin, while complete clearance reached 89% for genital psoriasis and 60% for scalp psoriasis, with no new safety concerns reported. The results support ICOTYDE as a potential important first-line systemic treatment and strengthen J&J’s immunology pipeline. J&J ICOTYDE psoriasis data
Positive Sentiment: Innovative Medicine growth remains a key offset: Analysts expect oncology products and newer launches to drive another quarter of growth, helping counter revenue erosion from Stelara biosimilars. This supports the investment case that J&J can replace lost exclusivity revenue with newer products. Innovative Medicine Q3 growth drivers
Positive Sentiment: IMAAVY adds pipeline support: New data in generalized myasthenia gravis gives investors additional evidence that J&J’s immunology portfolio could provide future growth beyond current blockbuster medicines. IMAAVY data update
Neutral Sentiment: J&J continues to receive favorable valuation commentary and analyst support after a strong one-year advance, but its approximately 30-times earnings valuation leaves less room for disappointment.
Negative Sentiment: Stelara biosimilar pressure remains the central risk: The expected decline in Stelara sales is weighing on near-term growth comparisons and may be contributing to investor caution despite positive pipeline news.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, September 22nd. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a report on Wednesday, July 15th. Argus set a $300.00 price objective on Johnson & Johnson in a research report on Wednesday, July 29th. Finally, Scotiabank reissued an “outperform” rating and set a $305.00 target price on shares of Johnson & Johnson in a research note on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $275.87.

Read Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Price Performance

The stock has a market cap of $616.79 billion, a price-to-earnings ratio of 29.66, a P/E/G ratio of 2.60 and a beta of 0.21. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company’s fifty day moving average is $266.52 and its two-hundred day moving average is $248.31.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period last year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, research analysts predict that Johnson & Johnson will post 11.54 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.11%.

Insider Transactions at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,779,963.81. This trade represents a 50.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is currently owned by insiders.

Institutional Trading of Johnson & Johnson

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Outlook Capital Management LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter valued at $28,000. Matrix Trust Co grew its stake in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares in the last quarter. Montgomery Financial Services LLC purchased a new position in Johnson & Johnson in the second quarter valued at about $43,000. Hyposwiss Advisors SA acquired a new position in Johnson & Johnson in the 4th quarter worth about $42,000. Finally, Bullseye Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $63,000. 69.55% of the stock is owned by institutional investors.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.